• Users Online: 361
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2012  |  Volume : 37  |  Issue : 2  |  Page : 135-139

Serum platelet-derived growth factor-BB in adult patients with aggressive non-Hodgkin’s lymphoma


1 Biochemistry Department, Faculty of Pharmacy, Faculty of Medicine, Mansoura University, Mansoura, Dakahliya, Egypt
2 Clinical Hematology Department, Faculty of Medicine, Mansoura University, Mansoura, Dakahliya, Egypt
3 Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Dakahliya, Egypt

Correspondence Address:
Emad Eldin Azmy
Clinical Hematology Department, Faculty of Medicine, Mansoura University, 35111 Mansoura, Dakahliya
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.7123/01.EJH.0000415411.50251.80

Rights and Permissions

Background

The importance of angiogenesis was proved first for solid tumors, and its importance in hematological malignancies was reported later.

Aim of the work

The present study aimed to evaluate the prognostic value of the angiogenesis marker platelet-derived growth factor-BB (PDGF-BB) in patients with aggressive non-Hodgkin’s lymphoma (NHL) and identify its significance on treatment response.

Subjects and methods

The serum level of PDGF-BB was measured in patients with aggressive NHL before and after chemotherapy and compared with that of a healthy control group, and its relationship with certain prognostic parameters was assessed.

Results

Pretreatment serum level of PDGF-BB did not show a significant change as compared with the control group. Its level showed no relation to Ann Arbor stages, International Prognostic Index scores, B symptoms, or extranodal involvement. Chemotherapy led to a considerable increase in serum PDGF-BB level in all NHL patients and in the noncomplete responder subgroup.

Conclusion

From the results mentioned above it could be concluded that PDGF-BB is not vital in the pathogenesis of NHL. Chemotherapy led to elevation of serum PDGF-BB, reflecting activation of angiogenesis, which can be considered one of the mechanisms of conferring chemoresistance to cancer cells or in identification of patients at risk for developing side effects. Future studies are recommended to prove this effect of chemotherapy. If this effect is confirmed, the use of agents blocking the angiogenic pathway of PDGF-BB in combination with chemotherapy may improve the therapeutic effectiveness and sensitize chemoresistant cells.



[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed938    
    Printed30    
    Emailed0    
    PDF Downloaded65    
    Comments [Add]    

Recommend this journal